Collegium Pharmaceutical Inc
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine… Read more
Collegium Pharmaceutical Inc (COLL) - Total Liabilities
Latest total liabilities as of September 2025: $1.33 Billion USD
Based on the latest financial reports, Collegium Pharmaceutical Inc (COLL) has total liabilities worth $1.33 Billion USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Collegium Pharmaceutical Inc - Total Liabilities Trend (2013–2024)
This chart illustrates how Collegium Pharmaceutical Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Collegium Pharmaceutical Inc Competitors by Total Liabilities
The table below lists competitors of Collegium Pharmaceutical Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Netmarble Games Corp
KO:251270
|
Korea | ₩2.52 Trillion |
|
Vipshop Holdings Limited
NYSE:VIPS
|
USA | $34.54 Billion |
|
Nordic American Tankers Limited
NYSE:NAT
|
USA | $465.84 Million |
|
Brigade Enterprises Limited
NSE:BRIGADE
|
India | ₹171.52 Billion |
|
Piramal Pharma Limited
NSE:PPLPHARMA
|
India | ₹81.16 Billion |
|
Jiangsu Leili Motor Corp Ltd
SHE:300660
|
China | CN¥2.71 Billion |
|
U.S. Physical Therapy Inc
F:UPH
|
Germany | €413.83 Million |
Liability Composition Analysis (2013–2024)
This chart breaks down Collegium Pharmaceutical Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.36 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 4.85 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.83 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Collegium Pharmaceutical Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Collegium Pharmaceutical Inc (2013–2024)
The table below shows the annual total liabilities of Collegium Pharmaceutical Inc from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $1.43 Billion | +51.36% |
| 2023-12-31 | $947.88 Million | -3.21% |
| 2022-12-31 | $979.29 Million | +100.20% |
| 2021-12-31 | $489.15 Million | +6.85% |
| 2020-12-31 | $457.81 Million | +109.17% |
| 2019-12-31 | $218.87 Million | +9.62% |
| 2018-12-31 | $199.66 Million | +534.08% |
| 2017-12-31 | $31.49 Million | +16.15% |
| 2016-12-31 | $27.11 Million | +114.37% |
| 2015-12-31 | $12.65 Million | -27.03% |
| 2014-12-31 | $17.33 Million | +402.06% |
| 2013-12-31 | $3.45 Million | -- |